Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyDisease description

Diagnosis

19 evidence topics · 16 sources

Routine laboratory tests: differential blood count, CRP or ESR, total IgE, and IgG anti-TPO

“We recommend limited investigations. Basic tests include differential blood count, CRP and/or ESR, and in specialized care total IgE and IgG anti‐TPO, and more biomarkers as appropriate. We recommend performing further diagnostic measures based on the patient history and examination, especially in patients with long standing and/or uncontrolled disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The basic tests include a differential blood count, CRP and/or ESR (to rule out severe systemic disease, as an indicator for parasitic disease, eosinophilic count, autoimmune disease such as systemic lupus), in all patients. In patients under specialist care, additional tests, such as total IgE and IgG‐anti‐TPO may be performed, as they indicate the likelihood of response to omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“However, although a clinical association between these laboratory markers and urticaria endotypes has been demonstrated, their clinical usefulness remains limited because there are no studies evaluating their diagnostic accuracy. Currently, cutoff points can be suggested but cannot be recommended for definitive endotype classification” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Intensive and costly general screening programs for causes of urticaria are not advised.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Disease activity instruments: UAS7 and AAS recommendations and score ranges

“We recommend the use of the urticaria activity score, UAS7, and/or of the angioedema activity score, AAS, for assessing disease activity in patients with chronic spontaneous urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The UAS7, calculated as the sum of daily scores over 7 consecutive days, should be routinely used to monitor disease activity and treatment response in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For CSU patients who develop angioedema, with or without wheals, the Angioedema Activity Score (AAS) should be used to assess disease activity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“CSU patients who experience wheals and angioedema should use the UAS7 and the AAS in combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the UAS7 the sum of the score (0–3 for wheals +0–3 for pruritis) for each day is summarized over 1 week (7 days) for a maximum of 42.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the AAS, scores are summed up to an AAS day sum score (0–15), 7 AAS day sum scores to an AAS week sum score (AAS7, 0–105), and 4 ASS week sum scores may be summed up to an AAS 4‐week sum score (AAS28, 0–420).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote